Wedbush Reiterates an 'Underperform' on Discovery Laboratories (DSCO); Financing Overhang Remains;
More News related to DSCO
- Discovery Laboratories (DSCO) Submits Propsed Protocol for Surfaxin Clinical to U.S. FDA
- Discovery Labs Submits SURFAXIN Pharmacodynamic Trial Protocol to FDA
- Discovery Labs to Present at the Lazard Capital Markets Healthcare Conference
- Wedbush Reiterates an 'Underperform' on Discovery Laboratories (DSCO); Financing Overhang Remains;
- Discovery Labs (DSCO) Posts Q3 Loss of 6c, In-Line with Street
More News related to Analyst Comments
- Sidoti & Co Initiates Coverage on Cytec Industries (CYT) with a Neutral
- Sidoti & Co Initiates Coverage on Gammon Gold (GRS) with a Neutral
- ThinkEquity Initiates Coverage on Curis (CRIS) with a Buy
- Raymond James Initiates Coverage on Simmons First National (SFNC) with an Outperform
- JMP Starts Investment Service Stocks: BLK, FII at Outperform, LM, BEN, JNS, TROW at Market Perform
Wedbush reiterates an Underperform rating on Discovery Laboratories (Nasdaq: DSCO)
Wedbush analyst says, "Management intends to explore strategic alternatives including potential additional financings as well as business alliances and commercial and development partnerships. Advancement of Surfaxin LS and Aerosurf depends upon the securitization of strategic alliances and necessary capital...Capital restraints remain an issue. The company ended Q3:09 with $17.7 million in cash, which is enough to sustain operations until Q1:10, per our estimates. Our estimates exclude capital available through two existing CEFFs as the floor prices are $0.60 and $1.15, respectively...Execution and financial risks remain our forefront concern. In addition, we view the remaining pipeline as one with inherent significant development risks."
To see more analyst ratings on DSCO Click Here.
Related Categories
Analyst CommentsStocks Mentioned
-0.02Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
